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After publication of the original article [1], the author
noticed that there are some error with Table 2 and
Table 3. Please see the correct Tables below. We
apologize for any inconvenience caused.
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Table 2 CXCL16 and CXCR6 expression as predictors of disease-










High 48 (14) NR 67
Low 227 (68) 98 56
Missing 60 (18)
Stromal cells .016
High 258 (77) 189 62




High 41 (12) 190 73
Low 245 (73) 122 55
Missing 49 (15)
CXCL16
Cancer cells + stromal
cells combined
.016
High/High 43 (13) NR 71
High/Low 182 (54) 190 58
Low/Low 41 (12) 47 48
Missing 69 (21)
NR, not reached; NCSLC, non-small cell lung cancer. Bold values
indicate p < 0.05
Table 3 Results of multivariate Cox regression analyses for
clinicopathological factors and CXCL16 in stromal cells (model 1)
and co-expression of CXCL16 in cancer and stromal cells (model 2*)
Factor HR CI 95% P
T-status <0.001†
T1 1.00
T2 1.60 (0.97-2.64) 0.065
T3 3.80 (2.13-6.77) <0.001
N-status <0.001†
N0 1.00
N1 2.01 (1.30-3.11) 0.002
N2 3.08 (1.74-5.44) <0.001
Differentiation 0.009†
Well 1.00
Moderate 1.17 (0.63-2.20) 0.618
Poor 2.08 (1.12-3.85) 0.020
Performance status 0.040†
ECOG 0 1.00
ECOG 1 1.52 (1.02-2.26) 0.040
ECOG 2 2.15 (0.94-4.91) 0.069
Vascular infiltration
No 1.00
Yes 1.70 (1.01-2.87) 0.046
Histology <0.001†
Squamous carcinoma 1.00
Adenocarcinoma 2.23 (1.48-3.35) <0.001
Large cell carcinoma 0.80 (0.39-1.66) 0.555
CXC16 stromal cells
Low 1
High 0.55 (0.35-0.87) 0.011
CXCL16 cancer and stromal cells* 0.031†
Low/Low 1.00
Low/High + High/Low 0.57 (0.35-0.93) 0.023
High/High 0.42 (0.20-0.88) 0.022
†Overall significance as prognostic marker. HR, Hazard ratio. Bold values
indicate p < 0.05
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